Featured Research

from universities, journals, and other organizations

Millions of mild asthma patients may not need daily inhaled steroid therapy, benefiting instead from taking only when symptoms occur

Date:
September 11, 2012
Source:
University of Texas Medical Branch at Galveston
Summary:
New research has shown that the millions of people who use corticosteroids prescribed daily to control mild asthma do no better than those who use them only when symptoms occur. The findings suggest a potential new treatment option that could change international standards of care, reduce patients' pharmacy costs, limit long-term exposure to corticosteroids and enable flexibility in managing the condition.

New research has shown that the millions of people who use corticosteroids prescribed daily to control mild asthma do no better than those who use them only when symptoms occur.

Related Articles


These findings suggest a potential new treatment option that could change international standards of care, reduce patients' pharmacy costs, limit long-term exposure to corticosteroids and enable flexibility in managing the condition, according to researchers at the University of Texas Medical Branch at Galveston, which led the study. Findings were published in the Sept. 12th issue of the Journal of the American Medical Association.

"The discovery that these two courses of treatment do not differ significantly could eventually change the way doctors and patients manage asthma, providing an option that is easier to follow and possibly less expensive," said lead author Dr. William J. Calhoun, Renfert Professor and Vice Chair for Research in Internal Medicine at UTMB. "Our findings build on a considerable foundation of research in the field and come at a time when asthma cases are rising at an alarming rate -- especially in lower-income communities."

Approximately 25 million people in the United States suffer from asthma; the disease costs about $3,300 per person each year in medical expenses, missed days of school and work, and early deaths.

Asthma is an inflammatory disease triggered by a wide range and combination of environmental and genetic factors. The assumption has been that because asthma is always present even if dormant, it should be treated with a continuous dose of anti-inflammatory medications, whether or not symptoms are present.

Accepted protocol is a twice-daily dose of an inhaled corticosteroid (ICS), such as beclomethasone or fluticasone, supplemented with "rescue" doses of albuterol to open the airways during onset of severe symptoms. Under physician-assessment-based adjustment (PABA), the standard of care, doctors adjust ICS dose based on assessment of symptoms, rescue use of albuterol and pulmonary function at six-week intervals.

More than 340 adult patients with mild-to-moderate persistent asthma participated in a randomized trial to assess different strategies for long-term asthma care: PABA; biomarker-based adjustment (BBA), in which a patient's levels of exhaled nitric oxide are monitored on a regular basis; and symptom-based adjustment (SBA), in which inhaled steroid medication is taken only when symptoms occur.

The researchers looked at several outcomes, including bronchial reactivity, lung function, days missed from school/work and exacerbation of symptoms and attacks, for each adjustment regimen over the course of nine months -- a timeframe that allowed them to adjust and account for seasonal variations. They found no measurable difference in outcomes among the three treatment methods.

The study also revealed an annual treatment failure rate of roughly 5 percent, with the significant exception of the physician-adjusted model, which doubled to more than 10 percent in the autumn and winter. The researchers believed this was due to a confluence of triggers, including fall allergens, increases in mold or indoor pollution and exposure to viral infections, among other common triggers.

This change in seasonal treatment failure with the physician-adjustment model confirms the need for "temporal personalization," or customized treatment that until now has not been possible. "SBA has the potential to allow us to personalize therapy in real time," Calhoun added. This is a vast improvement over current methods whereby even if a patient regularly sees a physician for reassessment, by the time the medication is adjusted, the patient can be six weeks or more behind the curve.

"There are often several orders of asthma symptom progression before an asthma attack ultimately occurs, resulting in a treatment failure or hospitalization," said co-author Dr. Bill T. Ameredes, Associate Professor, Division of Pulmonary and Critical Care Medicine at UTMB. "Patients using the SBA regimen can treat their symptoms on the spot which may prevent conditions from escalating to a full-blown attack. Further, since ICS have a longer duration of effect, patients will continue to reap the benefits from the initial SBA treatment days later, compared to using just a rescue inhaler."

In addition, the researchers found that good asthma control could be achieved using half the dose of inhaled steroids when the SBA approach was used -- providing potential pharmacy cost advantages.

Finally, SBA may also reduce possible risks of long-term use of ICS, including accelerated cataract development, vocal cord weakness and potential endocrine effects, as well as such side effects as mouth and throat irritation and oral yeast infections.

"The current protocol of daily ICS use is effective but the flexibility and immediate probable cost savings for asthma medicine that a symptom-based approach may offer will appeal to many patients," said Calhoun. "We hope our findings prompt patients to talk with their doctors and become more active participants in effectively managing their condition."


Story Source:

The above story is based on materials provided by University of Texas Medical Branch at Galveston. Note: Materials may be edited for content and length.


Journal Reference:

  1. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of Physician-, Biomarker-, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults With Asthma: The BASALT Randomized Controlled Trial. JAMA, 2012; 308 (10): 987-997 DOI: 10.1001/2012.jama.10893

Cite This Page:

University of Texas Medical Branch at Galveston. "Millions of mild asthma patients may not need daily inhaled steroid therapy, benefiting instead from taking only when symptoms occur." ScienceDaily. ScienceDaily, 11 September 2012. <www.sciencedaily.com/releases/2012/09/120911162027.htm>.
University of Texas Medical Branch at Galveston. (2012, September 11). Millions of mild asthma patients may not need daily inhaled steroid therapy, benefiting instead from taking only when symptoms occur. ScienceDaily. Retrieved December 20, 2014 from www.sciencedaily.com/releases/2012/09/120911162027.htm
University of Texas Medical Branch at Galveston. "Millions of mild asthma patients may not need daily inhaled steroid therapy, benefiting instead from taking only when symptoms occur." ScienceDaily. www.sciencedaily.com/releases/2012/09/120911162027.htm (accessed December 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, December 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Little Difference in Outcomes Among Strategies to Adjust Asthma Therapy, Research Finds

Sep. 11, 2012 Among adults with asthma controlled with low-dose inhaled corticosteroid therapy, the time to treatment failure was not significantly different among patients who received corticosteroid dose ... read more

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins